| Nome |
# |
|
CD8+CD28-CD127loCD39+regulatory T-cell expansion: A new possible pathogenic mechanism for HIV infection?, file e268c4c8-aebe-a6b7-e053-3a05fe0adea1
|
152
|
|
HCV elimination plan leads to significant benefits in managing liver-related diseases and hospital interventions: a regional simulation, file e268c4cb-7e3a-a6b7-e053-3a05fe0adea1
|
125
|
|
Treatment of hepatitis C virus genotype 4 in the DAA era, file e268c4ca-1a15-a6b7-e053-3a05fe0adea1
|
120
|
|
Bloodstream infections in patients living with HIV in the modern cART era, file e268c4c9-e122-a6b7-e053-3a05fe0adea1
|
116
|
|
Successful recovery of associated interstitial nephritis and focal segmental glomerulosclerosis in patients with HCV and HIV treated with sofosbuvir and daclatasvir and revision of literature, file e268c4c9-d020-a6b7-e053-3a05fe0adea1
|
112
|
|
How has the cost of antiretroviral therapy changed over the years? A database analysis in Italy, file e268c4c9-a7d0-a6b7-e053-3a05fe0adea1
|
109
|
|
Time to change the single-centre approach to management of patients with tuberculosis: a novel network platform with automatic data import and data sharing, file e268c4c8-b53d-a6b7-e053-3a05fe0adea1
|
108
|
|
Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: Results from a large observational cohort study (SCOLTA), file e268c4ca-614c-a6b7-e053-3a05fe0adea1
|
99
|
|
Rationale for an association between PD1 checkpoint inhibition and therapeutic vaccination against HIV, file e268c4c9-87be-a6b7-e053-3a05fe0adea1
|
98
|
|
Lipid profile improvement in virologically suppressed hiv-1-infected patients switched to dolutegravir/ abacavir/lamivudine: Data from the SCOLTA project, file e268c4ca-3981-a6b7-e053-3a05fe0adea1
|
98
|
|
Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in HIV/HCV co-infected patients, file e268c4cb-acef-a6b7-e053-3a05fe0adea1
|
92
|
|
Is it still worthwhile to perform quarterly CD4+ T lymphocyte cell counts on HIV-1 infected stable patients?, file e268c4c7-d420-a6b7-e053-3a05fe0adea1
|
89
|
|
AUMENTO DEGLI INDICI DI CITOLISI EPATICA NEI SOGGETTI CON INFEZIONE DA HIV CHE AVVIANO LA PRIMA LINEA DI TRATTAMENTO ANTIRETROVIRALE: STUDIO OSSERVAZIONALE DI COORTE, file e268c4cc-27fe-a6b7-e053-3a05fe0adea1
|
88
|
|
Weight gain: A possible side effect of all antiretrovirals, file e268c4ca-1a92-a6b7-e053-3a05fe0adea1
|
83
|
|
Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/ emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia, file e268c4cb-b194-a6b7-e053-3a05fe0adea1
|
83
|
|
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study, file e268c4ca-613c-a6b7-e053-3a05fe0adea1
|
69
|
|
Immunological profile of an infant treated with integrase inhibitor from the neonatal period, file e268c4c9-d757-a6b7-e053-3a05fe0adea1
|
65
|
|
Clinical characteristics, management and in-hospital mortality of patients with COVID-19 In Genoa, Italy, file e268c4cc-c929-a6b7-e053-3a05fe0adea1
|
25
|
|
Increasing prevalence of genitourinary schistosomiasis in Europe in the Migrant Era: Neglected no more?, file e268c4c7-b7c3-a6b7-e053-3a05fe0adea1
|
15
|
|
Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: different effects in different patients populations. Results from a large observational study, file e268c4ca-c9f6-a6b7-e053-3a05fe0adea1
|
12
|
|
Viremia copy-years and risk of estimated glomerular filtration rate reduction in adults living with perinatal HIV infection, file 4c590e71-c430-4115-ad09-465bf06a05f0
|
11
|
|
Bronchoalveolar lavage fluid characteristics and outcomes of invasively mechanically ventilated patients with COVID-19 pneumonia in Genoa, Italy, file e268c4cd-f66b-a6b7-e053-3a05fe0adea1
|
11
|
|
Prevalence of Viral Hepatitis in Unselected, Consecutively Enrolled Patients Hospitalised for SARS-CoV-2, file 8b10f9e0-4157-4a63-a9aa-e6204ca1a8a1
|
10
|
|
Ten Years of Medical Informatics and Standards Support for Clinical Research in an Infectious Diseases Network, file 9b956d61-09d0-4221-9267-da34592ddd87
|
10
|
|
null, file e268c4cd-7625-a6b7-e053-3a05fe0adea1
|
8
|
|
Higher mortality and intensive care unit admissions in COVID-19 patients with liver enzyme elevations, file 8304aec2-8fd5-45d6-984d-d259fbfaa197
|
6
|
|
Viremia copy-years and risk of estimated glomerular filtration rate reduction in adults living with perinatal HIV infection, file e268c4cd-78ab-a6b7-e053-3a05fe0adea1
|
6
|
|
Incidence and Prognosis of Ventilator-Associated Pneumonia in Critically Ill Patients with COVID-19: A Multicenter Study, file e268c4cd-9637-a6b7-e053-3a05fe0adea1
|
6
|
|
Computed tomography assessment of PEEP-induced alveolar recruitment in patients with severe COVID-19 pneumonia, file e268c4cd-e328-a6b7-e053-3a05fe0adea1
|
6
|
|
CD4+ T lymphocyte recovery in the modern antiretroviral therapy era: Toward a new threshold for defining immunological non-responders, file 2b2d883c-9dc1-4c84-baaf-8feba3ff57f2
|
5
|
|
Is it still worthwhile to perform quarterly CD4+ T lymphocyte cell counts on HIV-1 infected stable patients?, file e268c4cd-e468-a6b7-e053-3a05fe0adea1
|
5
|
|
Lamivudine resistance mutations in European patients with hepatitis B and patients co-infected with HIV and hepatitis B, file 9b44b8e5-d1be-4370-a8fb-deb7136fa803
|
4
|
|
Prevalence and prognostic value of cardiac troponin in elderly patients hospitalized for COVID-19, file e268c4cf-0177-a6b7-e053-3a05fe0adea1
|
4
|
|
Onychomadesis in a male patient with secondary syphilis, file e268c4ca-66b4-a6b7-e053-3a05fe0adea1
|
3
|
|
How relevant is the HIV low level viremia and how is its management changing in the era of modern ART? A large cohort analysis, file e268c4cb-9bb3-a6b7-e053-3a05fe0adea1
|
3
|
|
Tocilizumab and steroid treatment in patients with COVID-19 pneumonia, file e268c4cc-ab5a-a6b7-e053-3a05fe0adea1
|
3
|
|
Factors associated with hospital admission for COVID-19 in HIV patients, file e268c4cc-c4e8-a6b7-e053-3a05fe0adea1
|
3
|
|
Factors Associated With Weight Gain in People Treated With Dolutegravir, file 130e4347-efa5-4c6a-a653-c08d9d6bd436
|
2
|
|
Barriers to HCV micro-elimination in a cohort of people living with HIV (PLWH), file 169b480e-063a-44e7-8486-02122ee19448
|
2
|
|
Kidney disease and all-cause mortality in patients with COVID-19 hospitalized in Genoa, Northern Italy, file 289f0df2-993e-441f-8b16-3d0cac2a001d
|
2
|
|
Raltegravir-based therapy in a cohort of HIV/HCV co-infected individuals, file e268c4ca-1431-a6b7-e053-3a05fe0adea1
|
2
|
|
Ibalizumab and fostemsavir in the management of heavily pre-treated HIV-infected patients, file e268c4ca-1a1c-a6b7-e053-3a05fe0adea1
|
2
|
|
Missed opportunities to prevent mother-to-child transmission of HIV in Italy, file e268c4ca-52bf-a6b7-e053-3a05fe0adea1
|
2
|
|
Role of [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography for Diagnosis and Treatment of Sarcoidosis in an HIV-2-Infected Patient., file e268c4ca-5dc3-a6b7-e053-3a05fe0adea1
|
2
|
|
Is it time to re-think the use of etravirine in patients with available genotypic resistance test?, file e268c4ca-613f-a6b7-e053-3a05fe0adea1
|
2
|
|
Successful antiretroviral therapy by using unusual antiretroviral combinations in
heavily pre-treated patients: two case reports, file e268c4ca-87d5-a6b7-e053-3a05fe0adea1
|
2
|
|
HCV elimination plan leads to significant benefits in managing liver-related diseases and hospital interventions: a regional simulation, file e268c4cb-914b-a6b7-e053-3a05fe0adea1
|
2
|
|
Co-infezione HIV/HCV e malattia renale: un binomio “scindibile”, file e268c4cc-afdc-a6b7-e053-3a05fe0adea1
|
2
|
|
The switch from tenofovir disoproxil fumarate to tenofovir alafenamide determines weight gain in patients on rilpivirine-based regimen, file e268c4cc-b71e-a6b7-e053-3a05fe0adea1
|
2
|
|
Darunavir e incremento del peso corporeo: due diversi booster, stessi risultati, file e268c4cc-c460-a6b7-e053-3a05fe0adea1
|
2
|
|
Duration of isolation and precautions in immunocompromised patients with COVID-19, file e268c4cd-6a7f-a6b7-e053-3a05fe0adea1
|
2
|
|
Lung distribution of gas and blood volume in critically ill COVID-19 patients: a quantitative dual-energy computed tomography study, file e268c4cd-e59a-a6b7-e053-3a05fe0adea1
|
2
|
|
Early administration of bamlanivimab in combination with etesevimab increases the benefits of covid-19 treatment: Real-world experience from the liguria region, file e268c4ce-1cc8-a6b7-e053-3a05fe0adea1
|
2
|
|
Real-World Analysis of Survival and Clinical Events in a Cohort of Italian Perinatally HIV-1 Infected Children From 2001 to 2018, file e268c4ce-7668-a6b7-e053-3a05fe0adea1
|
2
|
|
Long-Term Effectiveness of Rilpivirine-Based Single-Tablet Regimens in a Seven-Year, Two-Center Observational Cohort of People Living with HIV, file 555a8661-5f74-4bd3-8563-51339d58f038
|
1
|
|
Case report: Sotrovimab, remdesivir and nirmatrelvir/ritonavir combination as salvage treatment option in two immunocompromised patients hospitalized for COVID-19, file 6669ed8d-3dc8-45b3-8b78-8e026fde92fe
|
1
|
|
Weight Gain in Overweight and Obese People with HIV—The OBHIV Cohort, file 74f21325-d91b-44dc-ab67-cd40e5bc1539
|
1
|
|
Trajectories of CD4+/CD8+ T-Cells Ratio 96 Weeks after Switching to Dolutegravir-Based Two-Drug Regimens: Results from a Multicenter Prospective Cohort Study, file cda5a060-c9b6-4f69-9bbc-fd47eb4075f4
|
1
|
|
Successful antiretroviral therapy by using unusual antiretroviral combinations in heavily pre-treated patients: two case reports, file e268c4c8-6a96-a6b7-e053-3a05fe0adea1
|
1
|
|
Bloodstream infections in patients living with HIV infection in the recent cART era: did something change?”., file e268c4c9-a078-a6b7-e053-3a05fe0adea1
|
1
|
|
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial, file e268c4c9-aab2-a6b7-e053-3a05fe0adea1
|
1
|
|
Short Communication: Tenofovir Disoproxil Fumarate/Emtricitabine Fits for All as Appropriate HIV-1 Pre-Exposure Prophylaxis?, file e268c4c9-ccce-a6b7-e053-3a05fe0adea1
|
1
|
|
Ligurian Vaccination in HIV Program (LIV in HIV): the experience of Genoa metropolitan area, file e268c4ca-0abe-a6b7-e053-3a05fe0adea1
|
1
|
|
Bedaquiline: A new hope for shorter and better anti-tuberculosis regimens, file e268c4ca-1a9e-a6b7-e053-3a05fe0adea1
|
1
|
|
Hepatitis C virus direct acting antivirals impact on renal function in the first 4 weeks of treatment, file e268c4ca-27e4-a6b7-e053-3a05fe0adea1
|
1
|
|
Switch from unboosted protease inhibitor to a single-tablet regimen containing rilpivirine improves cholesterol and triglycerides, file e268c4ca-38f6-a6b7-e053-3a05fe0adea1
|
1
|
|
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison, file e268c4ca-4fc8-a6b7-e053-3a05fe0adea1
|
1
|
|
Statins and Aspirin use in HIV-infected people: gap between European AIDS Clinical Society guidelines and clinical practice: the results from HIV-HY study, file e268c4ca-594d-a6b7-e053-3a05fe0adea1
|
1
|
|
HCV elimination plan leads to significant benefits in managing liver-related diseases and hospital interventions: a regional simulation, file e268c4ca-6145-a6b7-e053-3a05fe0adea1
|
1
|
|
Epidemiological and clinical features of hepatitis delta in HBsAg-positive patients by HIV status., file e268c4ca-7ce4-a6b7-e053-3a05fe0adea1
|
1
|
|
Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort, file e268c4cb-5d39-a6b7-e053-3a05fe0adea1
|
1
|
|
Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patients, file e268c4cb-884c-a6b7-e053-3a05fe0adea1
|
1
|
|
Treatment simplification to atazanavir/ritonavir+lamivudine versus maintenance of atazanavir/ritonavir+two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M), file e268c4cb-c7e0-a6b7-e053-3a05fe0adea1
|
1
|
|
null, file e268c4cc-c4ee-a6b7-e053-3a05fe0adea1
|
1
|
|
Missed opportunities in tb clinical practice: How to bend the curve? A medical, social, economic and ethical point of view, file e268c4cd-69f0-a6b7-e053-3a05fe0adea1
|
1
|
|
Extensive activation, tissue trafficking, turnover and functional impairment of NK cells in COVID-19 patients at disease onset associates with subsequent disease severity, file e268c4cd-c3e1-a6b7-e053-3a05fe0adea1
|
1
|
| Totale |
1.918 |